I am getting excited about going home.7 million for third quarter 2011 Auxilium Pharmaceuticals, Inc. , a specialty biopharmaceutical business, today announced financial outcomes and operational highlights for the one fourth ended September 30, 2011. For the 3rd one fourth of 2011, Auxilium reported net revenues of $66.7 million in comparison to net revenues of $53.6 million in the 3rd quarter of 2010.1) million, or $ per share, in comparison to a net lack of $ million, or $ per talk about, reported for the 3rd one fourth of 2010. ‘We think that the improvement we made in the 3rd one fourth of 2011 will get long term shareholder worth.1 million for the 3rd quarter 2011, up 130 percent versus the 3rd quarter of 2010.Net revenues of XIAFLEX in the U.S. Had been $10.3 million in the 3rd quarter 2011, up 124 percent versus the 3rd quarter of 2010.In August, Auxilium and BioSpecifics Technology Corp.In mice, withdrawal of BMP7 acts as an noisy alarms, restarting tumor development. These findings claim that therapies aimed at keeping or mimicking BMP7 expression can help prevent prostate tumor recurrence.. Bone cell factor may lull prostate tumor cells to sleep Prostate tumor cells could be lulled to rest by one factor released by bone cells, according to a report published on the web this week in the Journal of Experimental Medication ( Disease recurs in up to fifty % of prostate cancer sufferers after treatment, often due to metastases that pass on to distant organs.